How Analysts Feel About Cardiome Pharma Corp. (NASDAQ:CRME)?

February 15, 2018 - By Peter Erickson

 How Analysts Feel About Cardiome Pharma Corp. (NASDAQ:CRME)?
Investors sentiment increased to 1.09 in Q3 2017. Its up 0.26, from 0.83 in 2017Q2. It improved, as 2 investors sold Cardiome Pharma Corp. shares while 9 reduced holdings. 7 funds opened positions while 5 raised stakes. 13.54 million shares or 10.92% less from 15.20 million shares in 2017Q2 were reported.
18,731 were accumulated by Geode Capital Management Lc. Morgan Stanley invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). Jpmorgan Chase Company stated it has 158,697 shares. Putnam Invests Ltd Llc invested in 3.09 million shares or 0.02% of the stock. 600,625 were accumulated by Alphaone Inv Ser Ltd Limited Liability Company. Ardsley Advisory Ptnrs holds 36,200 shares or 0.01% of its portfolio. Renaissance Tech Ltd Liability Corp accumulated 0% or 411,413 shares. Royal Bancorporation Of Canada holds 0% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 1,889 shares. Toronto Dominion Natl Bank accumulated 84 shares. Comml Bank Of Montreal Can owns 0% invested in Cardiome Pharma Corp. (NASDAQ:CRME) for 1,004 shares. Rock Springs Cap Management Lp holds 0.12% of its portfolio in Cardiome Pharma Corp. (NASDAQ:CRME) for 1.20 million shares. Wells Fargo & Mn has invested 0% in Cardiome Pharma Corp. (NASDAQ:CRME). 27,658 are held by Virtu Financial Ltd. 10 are owned by State Bank Of Nova Scotia Trust Communication. Clough Cap Ptnrs Ltd Partnership accumulated 2.88 million shares.

Cardiome Pharma Corp. (NASDAQ:CRME) Ratings Coverage

Among 6 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cardiome Pharma Corp had 15 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating by Canaccord Genuity given on Wednesday, November 15. The firm has “Buy” rating by H.C. Wainwright given on Tuesday, August 22. The company was downgraded on Tuesday, August 11 by Zacks. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) earned “Speculative Buy” rating by Mackie on Friday, May 6. LB Securities reinitiated Cardiome Pharma Corp. (NASDAQ:CRME) rating on Friday, August 14. LB Securities has “Buy” rating and $12.50 target. The stock has “Buy” rating by Canaccord Genuity on Monday, July 17. The stock of Cardiome Pharma Corp. (NASDAQ:CRME) has “Buy” rating given on Wednesday, June 1 by H.C. Wainwright. The firm has “Buy” rating given on Friday, December 15 by Mackie. As per Wednesday, October 12, the company rating was downgraded by Mackie. The rating was maintained by Canaccord Genuity on Monday, August 21 with “Buy”. Below is a list of Cardiome Pharma Corp. (NASDAQ:CRME) latest ratings and price target changes.

15/12/2017 Broker: Mackie Rating: Buy Upgrade
22/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
15/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: $8 New Target: $5 Maintain
22/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.5 Maintain
21/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $8.0 Maintain

The stock increased 0.48% or $0.007 during the last trading session, reaching $1.467. About 13,876 shares traded. Cardiome Pharma Corp. (NASDAQ:CRME) has declined 11.02% since February 15, 2017 and is downtrending. It has underperformed by 27.72% the S&P500.

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. The company has market cap of $49.35 million. It offers BRINAVESS ) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It currently has negative earnings. The firm also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension.

More news for Cardiome Pharma Corp. (NASDAQ:CRME) were recently published by: Seekingalpha.com, which released: “Cardiome Pharma: The Pieces Are Coming Together” on May 25, 2017. Prnewswire.com‘s article titled: “Cardiome to Present at the Leerink Partners 7th Annual Global Healthcare …” and published on February 08, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.